DOI: 10.6084/m9.figshare.14955180
title: Analysis of the research articles selected for a systematic review of preclinical in vivo studies on lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke

description: The given dataset represent the coded analyses of the 87 studies selected for the systematic review on preclinical lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke<br><b>Search strategy</b><b> </b>The SYRCLE and PRISMA guidelines were taken into account during the realization of the systematic review. We sought out preclinical<i> in vivo</i> studies that employed lentivirus (LV) or adeno-associated virus (AAV) mediated gene therapy approaches for the treatment of cerebral ischemic stroke. A systematic search of online databases PubMed, Scopus, and Web of Science (All Databases) was performed on April 10, 2020, and updated on January 7, 2021, to cover all publications published until the end of 2020. Titles, abstracts, and keywords were searched by the following syntax: (genes OR gene) AND (therapy OR therapeutics) AND (AAV OR lentivirus) AND (brain OR neurons OR neuron OR astrocytes OR neuroglia OR glia OR microglia) AND (stroke OR ischemia OR ischemic). No language or publication date restrictions were applied.<b> </b><b>Inclusion criteria</b><b> </b>The following inclusion criteria were used to screen the retrieved titles and the abstracts: (1) the study produced new, original results (primary research article), (2) it was a preclinical ischemic stroke study, i.e., it used <i>in vivo</i> ischemic stroke animal model, (3) the viral gene transfer was used as a therapeutic intervention, (4) types of viral vectors used were LV or AAV, and (5) the virus was applied directly into the animal. Excluded were perinatal studies or on pups before reaching sexual maturity, and all in vitro application of viruses, even to the cells subsequently transplanted to the animals. In case of doubt whether the publication meets the inclusion or exclusion criteria, the full-text screening was performed. Finally, reference lists from publications fulfilling the inclusion criteria were used to identify additional relevant studies.<b>Data extraction </b>The content of publications identified by the search were analyzed in detail. We extracted the information about the viral vector type, vector envelope, virus titer, and gene promotor type used for gene therapy. The applied intervention was reconstructed including a virus delivery route, location, and time point of administration as well as total volume and number of viral particles injected. Additionally, we coded data on animal species, strain, age, sex, stroke model, and ischemia duration. Lastly, we recorded details about transduction efficiency assessment (methods, time point, and outcome) and outcome measures regarding infarct volume, neurobehavioral outcomes as well as any other relevant results.<br><b>Dataset </b>The Table given here contains all the data collected and coded as described above for the total of 87 studies selected.The dataset was used for the article currently under review:Skukan L, Brezak M, Ister R, Klimaschewski L, Vojta A, Zoldoš V, Gajović S. Lentivirus- or AAV-mediated gene therapy interventions in ischemic stroke: a systematic review of preclinical in vivo studies. J Cereb Blood Flow Metab, under review <br>